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Erythrocyte invasiona b s t r a c t
Plasmodium vivax parasites cause the majority of malaria cases outside Africa, and are increasingly being
acknowledged as a cause of severe disease. The unique attributes of P. vivax biology, particularly the
capacity of the dormant liver stage, the hypnozoite, to maintain blood-stage infections even in the
absence of active transmission, make blood-stage vaccines particularly attractive for this species.
However, P. vivax vaccine development remains resolutely in first gear, with only a single blood-stage
candidate having been evaluated in any depth. Experience with Plasmodium falciparum suggests that a
much broader search for new candidates and a deeper understanding of high priority targets will be
required to make significant advances. This review discusses some of the particular challenges of P. vivax
blood-stage vaccine development, highlighting both recent advances and key remaining barriers to over-
come in order to move development forward.
 2016 Published by Elsevier Ltd on behalf of Australian Society for Parasitology.1. Still looking for the on-ramp in the Plasmodium vivax vaccine
roadmap
Plasmodium falciparum and Plasmodium vivax both emerged
from African apes early during human evolution (Liu et al., 2010,
2014), but their subsequent history has been very different. While
P. falciparum cases are still concentrated in Africa, with a relatively
light, although highly impactful, footprint in the rest of the world,
P. vivax parasites dominate Asia and the Americas, causing the
majority of malaria outside Africa (Gething et al., 2012). Detailed
clinical studies have made it clear that while the majority of
P. vivax cases are asymptomatic, P. vivax infections can be severe
and result in mortality (Baird, 2013). This revelation, coupled with
concerns about emerging P. vivax drug resistance, have led to a
renewed interest in this neglected tropical disease, and concerted
discussions about a P. vivax-specific elimination strategy. The bio-
logically distinct life cycle of P. vivax, with high transmission
potential and a dormant liver stage, the hypnozoite, make it clear
that control strategies will not simply be able to be transferred
from P. falciparum (Mueller et al., 2009). While effective treatments
for blood-stage P. vivax exist, primarily artemisin-combination
therapies (ACTs), treatment for hypnozoites is limited to one drug(primaquine) that is contra-indicated by glucose-6-phosphate
dehydrogenase (G6PD) deficiency, a common phenotype in many
malaria endemic regions (Baird et al., 2012).
Given the unknown burden of hypnozoites, which can cause
relapse and trigger blood-stage infections even in the absence of
continued transmission, an effective blood-stage vaccine would
be a particularly useful tool for P. vivax elimination, as well as
reducing the burden of disease. However, there is currently no
effective vaccine for P. vivax. This statement, which has been made
in one guise or another in the introduction to almost every review
on malaria vaccine development for the last 10 years, in fact
understates the current situation for P. vivax. Whereas P. falciparum
vaccine research has progressed inexorably forward, moving to
large-scale testing of panels of antigens and with one candidate
reaching Phase III trials (Rts, 2015), the majority of P. vivax vaccine
development is resolutely still in early preclinical development
(Mueller et al., 2009). Human clinical trials have to date only been
carried out for two P. vivax antigens. A vaccine based on the pre-
erythrocytic candidate Circumsporozoite Protein (PvCSP) was
well-tolerated in a recent Phase I/IIa trial, inducing antibody and
cell-mediated immune responses and resulting in a delay in the
median prepatency period for all vaccinated individuals (Bennett
et al., 2016). While the prepatency period was delayed by up to
2 days, no sterile protection was achieved, and just as with the
development of CSP-based vaccines for P. falciparum has taken an
extended period of time, it is clear that much more work awaitsoi.org/
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transmission-blocking candidate Pvs25, induced antibody
responses that could block P. vivax transmission (Malkin et al.,
2005; Wu et al., 2008), but again much work is required to move
beyond this initial study. All other potential antigens remain
resolutely at the preclinical stage, although in the case of one
blood-stage candidate, P. vivax Duffy Binding Protein (PvDBP), this
preclinical development has been extensive (reviewed in (Mueller
et al., 2015), and a Phase Ia trial of a virally vectored PvDBP vaccine
(de Cassan et al., 2015) has recently been completed (https://clin-
icaltrials.gov; trial NCT01816113). The detailed advancement of
only a single blood-stage candidate is in marked contrast to the
more extensive testing of candidates for P. falciparum, where the
number of candidates under active investigation reflects the com-
plexity of the erythrocyte invasion process, which involves pro-
teins located in multiple intracellular organelles (Fig. 1). If we are
to advance blood-stage P. vivax vaccine development in any signif-
icant manner, new tools and detailed studies of emerging candi-
dates will be needed. This review discusses the emergence of
some such tools and identifies the key gaps that remain on the path
to P. vivax vaccine development.2. Broader – expanding the range of candidates using new tools
Malaria vaccine research has an extensive history and is based
on seminal findings that productive immunity can be generated
following repeated experimental exposure to parasite infection
(Collins and Jeffery, 1999) or by passive transfer of antibodies
(Cohen et al., 1961). Identifying the best vaccine antigens has fix-
ated the field ever since, especially since the true scale of potential
targets was revealed with the publication of the first P. falciparum
genome in 2002 (Gardner et al., 2002), followed in 2008 by the P.
vivax genome (Carlton et al., 2008). It has taken some years for
the scale of Plasmodium vaccine research to begin to match the
scale of the Plasmodium genome, with the vast majority of research
focussing on only a handful of antigens, which not coincidentally
were also among the first Plasmodium genes cloned (Conway,
2015). A significant portion of this lag can be attributed to the fact
that almost any vaccine candidate research requires expression of
recombinant antigens and Plasmodium proteins have been
consistently some of the most difficult proteins to express. TheFig. 1. A schematic representation of a Plasmodiummerozoite showing several of the ma
currently in clinical development are shown according to their respective localisation
Protein; EBA, erythrocyte-binding antigen; AMA, apical membrane antigen; PfPH5, P. fal
falciparum; MSP, merozoite surface protein; SERA, serine repeat antigen.
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Plasmodium genomes can exceed 80%, which makes manipulating
Plasmodium DNA into expression constructs difficult and results
in amino acid biases that are not always well tolerated by the stan-
dard eukaryotic or prokaryotic protein expression systems. Added
to this is the apparent lack of N-linked glycosylation in Plasmodium
parasites but presence of canonical N-linked glycan sites within
their antigens, which means that their expression in some eukary-
otic systems can result in aberrant glycosylation and production of
distinctly non-native proteins. For too many years, those that
aspired to express Plasmodium proteins were routinely frustrated
by insoluble pellets and vanishingly small yields.
Two developments have radically improved our ability to
express Plasmodium proteins. Perhaps most significantly, if also
most trivially, the cost of DNA synthesis has dropped dramatically
in recent years. This has facilitated molecular cloning and allowed
researchers to easily optimise both AT content and codon usage to
suit the specific expression system that they are using. In parallel,
much more scalable expression systems have been developed,
allowing expression of up to hundreds of genes simultaneously
and the first systematic screens of potential Plasmodium vaccine
antigens and immune targets. A widely applied approach has been
the use of an Escherichia coli cell-free in vitro transcription-
translation system, which enabled printing of slides with hundreds
of antigens (Doolan et al., 2008) and large-scale screening of epi-
demiological cohorts for P. falciparum antigens (Crompton et al.,
2010; Dent et al., 2015). While bacterial in vitro transcription–tra
nslation systems have the advantage of scale, they have the disad-
vantage of producing proteins in an extracellular reducing environ-
ment and expressed proteins can thus lack disulphide bonds, post-
translational modifications or other elements of native tertiary
structure. Linear epitopes are preserved but some conformational
and functional epitopes may be lost, which is a particular concern
for extracellular proteins which include most Plasmodium vaccine
targets. Proteins produced in this platform for use on arrays are
not purified, which presents other limitations. An alternative
in vitro transcription–translation approach is the wheat-germ cell
free expression system, which has been shown to successfully pro-
duce active proteins with tertiary structure, and vaccines based on
this platform induce functional immune responses (Miura et al.,
2013; Tsuboi et al., 2010). Large-scale wheat-germ proteinjor structures and organelles. Plasmodium vivax and Plasmodium falciparum antigens
to either the surface coat, rhoptries or micronemes. PvDBP, P. vivax Duffy Binding
ciparum reticulocyte binding-like homologue 5, GLURP, glutamate-rich protein of P.
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studies to identify blood-stage targets of protective antibodies to
P. falciparum malaria (Richards et al., 2013). Alternative eukaryotic
expression systems have also proven effective. The HEK293
system, which can express large proteins of >200 kDa, has been
successfully applied to the major cytoadherence factors, P. falci-
parum Erythrocyte Membrane Proteins or PfEMP1 (Srivastava
et al., 2013). It has also been used to generate a library of 62 P. fal-
ciparum merozoite proteins (Crosnier et al., 2013; Zenonos et al.,
2014), which have been applied to identify novel merozoite–ery-
throcyte interactions such as that between PfRh5 and Basigin
(Crosnier et al., 2011) as well as for large-scale immuno-
epidemiological screening to prioritise P. falciparum blood-stage
vaccine targets (Osier et al., 2014b).
Such tools are now also being applied to P. vivax antigen discov-
ery. Libraries of in vitro transcribed–translated P. vivax antigens
have now been generated and used to interrogate immune
responses in individuals either experimentally challenged with
(Arevalo-Herrera et al., 2016) or naturally exposed to (Chen et al.,
2010; Chuquiyauri et al., 2015) P. vivax. The Human Embryonic
Kidney 293E cell (HEK293E) system has also now been applied to
P. vivax blood-stage antigens, with a library of 34 full-length extra-
cellular domains of P. vivax merozoite proteins successfully
expressed and available through free vector repositories
(Hostetler et al., 2015). Screening this library against sera from P.
vivax-infected Cambodian patients revealed high seroreactivity
and established that the majority of antigens contained heat-
labile epitopes, and therefore likely retained tertiary structure.
Screening samples from longitudinal cohort studies in the Solomon
Islands and Papua New Guinea revealed three P. vivax merozoite
antigens (merozoite proteins P12 and P41, and PVX_081550) asso-
ciated with reduced risk of uncomplicated P. vivaxmalaria, none of
which have received extensive study previously (Franca et al.,
2016). The wheat-germ cell free system has similarly been valu-
able in studies of P. vivax (Charnaud et al., 2016; Cheng et al.,
2013). It is exactly for such a purpose, identifying new candidates
in a systematic and unbiased manner, that such protein libraries
are valuable.
While their application is still in the earliest stages, the pres-
ence of such tools is a significant boost to the field – combining
those with well-designed cohort studies to search for evidence that
specific antigens are targets of immune responses associated with
protection is the next obvious step. Using cohort studies to identify
potential immune targets and vaccine candidates is particularly
valuable for P. vivax due to the inability to readily culture the par-
asite and test vaccine-induced antibodies for functional activity, an
approach that has been extensively used of P. falciparum. To date
very few P. vivax blood-stage antigens have been studied in this
manner; among the better studied are PvDBP, Merozoite Surface
Proteins PvMSP1, PvMSP3a, PvMSP9, and Apical Membrane
Antigen PvAMA1 (Cutts et al., 2014). The majority of studies have
evaluated acquisition and prevalence of antibodies, while few have
assessed associations with protection in longitudinal cohorts.
Antibodies that blocked binding of PvDBP to the Duffy Antigen
Receptor for Chemokines (DARC) were associated with a reduced
risk of high density parasitemia in children (King et al., 2008). Anti-
body reactivity alone has not been strongly associated with protec-
tion but there is evidence of strain-specific protective effects of
antibodies (Cole-Tobian et al., 2009; Souza-Silva et al., 2010). These
observations highlight the need for functional assays to assess
immunity (discussed further below) and the need to account for
parasite genetic diversity in studies of immunity. Antibodies to
PvMSP3a were associated with a reduced risk of P. vivax malaria
in one study of young children (Stanisic et al., 2013), and a meta-
analysis of two studies in Brazil found a protective association
for antibodies to the PvMSP1 N-terminal region (Cutts et al.,Please cite this article in press as: Tham, W.-H., et al. Plasmodium vivax vaccine
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dence from studies of P. falciparum indicate that effective immu-
nity is mediated by antibodies to specific combinations or
repertoires of antigens, rather than single antigen-specific
responses (Crompton et al., 2010; Osier et al., 2014b; Richards
et al., 2013), studies that are now becoming possible in P. vivax.
The significant differences between P. falciparum and P. vivax in
the function and structure of specific merozoite proteins (Beeson
et al., 2016), including proteins that do not have obvious 1:1 ortho-
logues between the two species (e.g. vaccine candidates PfMSP2
and Reticulocyte Binding-like homologous protein 5 (PfRh5)), indi-
cate that knowledge on the targets of immunity to P. falciparum,
and the prioritisation of specific P. falciparum vaccine candidates,
will have only partial translation to P. vivax.3. Deeper – using detailed functional studies to guide antigen
design
As well as extending the number of P. vivax antigens being
screened for vaccine potential, there is also a clear need for much
more detailed functional studies of high priority antigens. Until
recently, the only blood-stage P. vivax antigen studied in this fash-
ion has been PvDBP. Plasmodium vivax invasion is reliant on the
interaction between PvDBP and its DARC. The receptor-binding
domain of PvDBP maps to a conserved cysteine-rich Duffy
binding-like domain called Region II (PvDBP-RII) (Adams et al.,
1992). Structural studies show that PvDBP-RII engages DARC in a
multi-step binding process that results in the dimerisation of
PvDBP bound to two molecules of DARC (Batchelor et al., 2011,
2014). Naturally acquired anti-PvDBP-RII antibodies that disrupt
the PvDBP-DARC interaction and P. vivax invasion have epitopes
that localise to regions that interact with DARC (Chootong et al.,
2012). However, the presence of polymorphic residues such as
the DEK epitope, that flank conserved epitopes required for DARC
binding, provides a major challenge for vaccine design (Chootong
et al., 2010). It is thought that these polymorphisms divert the
human immune response away from the conserved functional resi-
dues while also generating strain-specific responses, thus limiting
the efficacy of anti-PvDBP-RII antibodies to target multiple strains.
To overcome this problem, an alternative epitope called DEKnull
has been designed which is devoid of the polymorphisms that flank
the conserved functional residues (Ntumngia and Adams, 2012).
This engineered antigen does not alter the conformation or
immunogenic properties of PvDBP and is able to elicit inhibitory
antibodies that block binding (Chen et al., 2015). Further progress
on PvDBP has also been made through the identification of broadly
neutralizing epitopes that target motifs not involved in receptor
binding and dimerisation that are highly conserved among PvDBP
alleles (Chen et al., 2016). These studies expand the repertoire of
inhibitory epitopes that may be more effective in strain-
transcending protection. This detailed scientific investigation,
encompassing atomic resolution structures of PvDBP, structure–
function analyses, extensive identification of polymorphisms in
clinical isolates and immuno-epidemiology studies, has allowed
definitive advances for the development of PvDBP as a viable vac-
cine candidate.
Experience of vaccine development in P. falciparum suggests
that a single antigen alone is unlikely to be successful in a vaccine,
so applying some of the lessons learned from study of PvDBP to
other candidates will be important. One family of candidates
where such methods are now being applied is the P. vivax Reticu-
locyte Binding Proteins (PvRBPs), which mediate the specificity of
P. vivaxmerozoites for reticulocytes (Galinski et al., 1992). Genome
sequencing of several P. vivax isolates identified 11 PvRBP family
members that are comprised of five full-length genes (pvrbp1a,research – we’ve only just begun. Int. J. Parasitol. (2016), http://dx.doi.org/
Fig. 2. Superimposition of Plasmodium vivax reticulocyte binding protein 2a
(PvRBP2a; magenta) and Plasmodium falciparum reticulocyte binding-like homo-
logue 5 (PfRh5; teal) structures in ribbon representation. Protein Data Bank (PDB –
http://www.rcsb.org/pdb), accession code for PfRh5:4WAT and PvRBP2a:4Z8N,
respectively. The cysteine residues forming an overlapping disulphide bridge are
shown as yellow sticks. The cysteine bond between C299 and C303 in PvRBP2a
overlaps with the bond between C345 and C351 in PfRh5. The presence of the loop
and residues within the loop such as Asn347 in PfRh5 have been implicated to be
important for red blood cell binding and host tropism.
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pvrbp2p1, pvrbp2p2) and three pseudogenes (pvrbp2d, pvrbp2e,
pvrbp3) (Carlton et al., 2008; Hester et al., 2013). Almost all PvRBP
proteins have a signal peptide at the N terminus and the full-length
genes encode large molecular weight proteins of over 280 kDa. Lit-
tle is known about the majority of family members, although sev-
eral PvRBP genes are expressed in late schizont stages (Bozdech
et al., 2008), and analyses of 15 Thai isolates shows that Pvrbp
genes can vary in expression between patient samples (Hietanen
et al., 2015). All are presumed to bind red blood cells, based on
the initial finding that PvRBP1a and PvRBP2c are expressed at the
apical tip of P. vivax merozoites and form a high molecular weight
complex that binds reticulocytes (Galinski et al., 1992). A more
recent study shows that PvRBP2a bound both normocytes and
reticulocytes, opening up the possibility that other members of
the PvRBP family may have different specificities for mature and
young red blood cells (Gruszczyk et al., 2016). In all cases, the iden-
tities of their cognate receptors remain unknown and this high-
lights an important knowledge gap in P. vivax biology (Mueller
et al., 2009). However, their role in red blood cell invasion, and
the fact that they are all orthologues of PfRh5, one of the leading
P. falciparum blood-stage vaccine candidates (Bustamante et al.,
2013; Crosnier et al., 2011; Douglas et al., 2011, 2015), makes them
ideal candidates for detailed molecular follow-up and antigen
refinement.
This process has recently begun with the determination of the
crystal structure of PvRBP2a (Gruszczyk et al., 2016), with the
red blood cell binding domain showing a three-dimensional archi-
tecture similar to PfRh5 (Chen et al., 2014; Wright et al., 2014).
PfRh5 binds to the erythrocyte receptor Basigin to mediate an
essential step in P. falciparum entry into red blood cells (Crosnier
et al., 2011). The crystal structures of PfRh5 and PvRBP2a define
the structural fold of the red blood cell binding domains of PvRBP
and PfRh protein families, but while these domains have similar a-
helical scaffolds, their properties must still allow engagement with
different red blood cell receptors. While the receptor for PvRBP2a is
yet to be identified, it is unlikely to be Basigin as PvRBP2a binding
to red blood cells is sensitive to trypsin treatment whereas PfRh5
binding to Basigin is trypsin-resistant (Galinski et al., 1992;
Gruszczyk et al., 2016; Hayton et al., 2008). A major difference
between PfRh5 and PvRBP2a is the distribution of the charged
amino acid residues exposed on the surface, particularly within
the binding interface between PfRh5 and Basigin (Gruszczyk
et al., 2016; Wright et al., 2014). The corresponding area within
PvRBP2a has predominantly negative electrostatic potential and
mutational analyses introducing positively charged residues result
in the abolishment of PvRBP2a binding to red blood cells. These
distinct charge properties may be one of the key features that
allow the engagement with different red blood cell receptors.
As has been the case for PvDBP, analysis of the PvRBP2a struc-
ture helps to define inhibitory epitopes and refine vaccine antigen
design. Structural comparisons of PfRh5 and PvRBP2a show that
the placements of the disulphide bridges are conserved (Chen
et al., 2014; Gruszczyk et al., 2016; Wright et al., 2014). In partic-
ular the bonded pair of cysteine residues between C345 and C351
in PfRh5 overlaps with C299 and C303 in PvRBP2a, and this disul-
phide bridge is important for the function of both proteins (Fig. 2).
A co-crystal structure of PfRh5 with a Fab fragment of QA1, a mon-
oclonal antibody that blocks PfRh5-Basigin interaction and inhibits
parasite growth in vitro (Douglas et al., 2014), shows that QA1
binds a conformational epitope presented by the disulphide loop
held by C345 and C351. The presence of a disulphide loop is also
required for PvRBP2a function as mutation of C299 and C303 to
serine residues results in a loss of the capability of PvRBP2a to bind
erythrocytes while not altering the structural conformation of the
protein (Gruszczyk et al., 2016). Collectively, these resultsPlease cite this article in press as: Tham, W.-H., et al. Plasmodium vivax vaccine
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PvRBP and PfRh red blood cell binding domains as a target for inhi-
bitory antibodies. Future investigations should explore conforma-
tional mimotopes as immunogens that may generate cross-
inhibitory antibodies that inhibit PvRBP and PfRh function in par-
asite invasion.
In PvDBP research, the combination of structural biology and
the study of natural immune responses and genetic variants has
been particularly powerful. Initial studies show that PvRBPs are
also targets of naturally acquired human antibodies in malaria
endemic regions. Plasma IgG from 41 Thai individuals infected
with P. vivax show that total IgG levels to the five full-length PvRBP
proteins were positively correlated with age, reflective of their
cumulative exposure to P. vivax (Hietanen et al., 2015). Naturally
acquired antibodies to PvRBP1a were prevalent in three Brazilian
Amazon populations with the highest immune responses to
regions outside the red blood cell binding domain and shown to
be biased towards the cytophilic subclasses IgG1 and IgG3 (Tran
et al., 2005). Immune responses of 16 P. vivax-infected individuals
from the Republic of Korea were analysed using a collection of in
silico predicted linear B cell epitopes from nine PvRBP sequences
(Han et al., 2015). A peptide within the binding domain of PvRBP2c
showed a high humoral response level while other PvRBP peptides
that represent high antigenicity were outside the conserved red
blood cell binding regions. While these studies show that malaria
endemic populations generate antibodies against PvRBPs, it will
be important in future work to determine which PvRBP antibody
responses elicit antibodies correlated with clinical protection.
Based on the importance of the disulphide loop in PvRBP receptor
engagement, it will be critical to maintain the structural conforma-
tion of PvRBP proteins used in immuno-epidemiology studies and
for mapping epitopes of naturally acquired inhibitory antibodies.4. Blood-stage immune mechanisms for P. vivax
As well as identifying new blood-stage targets and studying
them in molecular depth, we will also need a strong understanding
of the mechanisms that mediate immunity to P. vivax malaria if
highly efficacious long-lived vaccines are to be developed. Knowl-
edge about mechanisms of immunity to P. vivax malaria is limited,
largely because it is not currently possible to culture P. vivax
in vitro for an extended period of time. As a result, most knowledge
on immune mechanisms to P. vivax are borrowed from insights on
P. falciparum, or other Plasmodium spp. in animal models. While it
seems reasonable to assume that the key principles of immunity toresearch – we’ve only just begun. Int. J. Parasitol. (2016), http://dx.doi.org/
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between the two species warrant caution and the relative impor-
tance of specific mechanisms may differ between the species.
Antibodies are known to play a major role in immunity to the
blood stages of P. falciparum and target merozoites, and it is
assumed to be similar for P. vivax (reviewed in Beeson et al.,
2016). For P. falciparum, the ability of antibodies to directly inhibit
invasion of merozoites and/or blood-stage growth has long been
regarded as an important mechanism of immunity, and the
in vitro growth inhibition assay (GIA) is the most widely used assay
to evaluate functional activity of antibodies to merozoite antigens
(Bergmann-Leitner et al., 2006; Persson et al., 2006). For P. vivax,
antibodies to selected antigens, including PvDBP and PvAMA1,
have been shown to inhibit growth in vitro (Grimberg et al.,
2007b; Vicentin et al., 2014), although such studies are far thinner
on the ground in this species due to the difficulties associated with
in vitro culture. It should be noted that antibody activity in the GIA
has not been consistently predictive of acquired human immunity
or vaccine-induced immunity with P. falciparum (Duncan et al.,
2012; McCallum et al., 2008), emphasising the importance of eval-
uating other effector mechanisms of antibodies to merozoites. One
valuable approach has been the use of assays that measure the
ability of antibodies to inhibit the binding of invasion ligands to
red blood cell surface receptors. This has the advantage of not
requiring cell culture, which is still a major challenge for P. vivax,
and provides data on antigen-specific functional antibody activity.
This approach has been most applied to studies of antibody inhibi-
tion of the binding of PvDBPII to its receptor, DARC (Grimberg et al.,
2007a; VanBuskirk et al., 2004) and binding inhibitory antibodies
to PvDBPII has been associated with protection from malaria in
children (King et al., 2008). Similarly, in P. falciparum antibodies
that inhibited the binding of the related invasion ligand EBA175
were associated with protection from symptomatic malaria (Irani
et al., 2015).
While much attention has focussed on GIA and direct antibody
inhibition of receptor–ligand interactions, components of cell-
mediated immunity are also important, including roles for Fc-
receptor mediated parasite clearance (by monocytes, macrophages
and neutrophils), and T-cell help for antibody production and
memory responses (reviewed in (Beeson et al., 2008; Langhorne
et al., 2008). Antibodies to P. vivax and P. falciparum blood-stage
antigens are formed predominantly by the IgG1 and IgG3 sub-
classes (Beeson et al., 2016; Cutts et al., 2014), which can interact
with Fc-receptors on a range of immune cells, as well as comple-
ment. Evidence in P. falciparum indicates that naturally-acquired
and vaccine-induced antibodies can opsonise merozoites for
phagocytosis or killing by monocytes and neutrophils (Hill et al.,
2013; Joos et al., 2010; Osier et al., 2014a), and these effector
mechanisms have been associated with protection from P. falci-
parummalaria in longitudinal studies. Monocytes can also mediate
antibody-dependent growth inhibition of P. falciparum through the
release of soluble inhibitors, a mechanism referred to as antibody-
dependent cellular inhibition or ADCI (Bouharoun-Tayoun et al.,
1990). A role for Fc-receptors in immunity has also been demon-
strated in rodent models (McIntosh et al., 2007). Currently, little
data exists for P. vivax, but it seems likely that similar mechanisms
would play an important role. A recent study reported a role for
specific monocyte subsets in the clearance of P. vivax-infected
reticulocytes (Chimma et al., 2009), with similar findings in P. fal-
ciparum (Zhou et al., 2015). Antibodies to P. falciparum merozoites
can also fix and activate complement on the merozoite surface to
inhibit blood-stage replication by direct inhibition of invasion
and merozoite lysis (Boyle et al., 2015). In the absence of specific
antibodies, complement deposition on the merozoite surface is
limited due to the presence of regulatory factors (Boyle et al.,
2015; Kennedy et al., 2016; Rosa et al., 2016). Whether the samePlease cite this article in press as: Tham, W.-H., et al. Plasmodium vivax vaccine
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In P. falciparum, much research has focussed on infected erythro-
cyte surface antigens, especially PfEMP1, as targets of immunity
and as potential vaccine candidates (Chan et al., 2014). Since there
are no orthologues of PfEMP1 in P. vivax, surface antigens of P.
vivax-infected erythrocytes have not been a significant focus of
the vaccine effort.
While the above focuses on cell and protein-based assays, P.
vivax infection models in non-human primates are also valuable
in evaluating P. vivax vaccines and studying immunity. They also
offer the advantage of being able to study relapses and hypno-
zoites. Aotus and Saimiri monkeys can both be used to study P.
vivax infection using adapted isolates, and rhesus macaques can
be used to study the closely related simian malaria, Plasmodium
cynomolgi (Joyner et al., 2015). Non-human primate models will
continue to play an important role in P. vivax development, how-
ever access, cost and ethical considerations limit their use for
larger-scale screening approaches.5. A roadmap for the near future
The P. vivax community now possesses several new tools and
knowledge that should allow significant scale-up of vaccine
research. Panels of recombinant P. vivax antigens expressed in a
number of different systems will allow systematic screening for
new targets, and the detailed biochemical and functional tools that
have been applied to PvDBP, and more recently to members of the
PvRBP family, are ready to be applied to any high priority targets
identified in such screens. However, two significant roadblocks
remain. Firstly, the current inability to maintain P. vivax in long-
term culture means that many of the functional approaches used
to understand immune function or evaluate antigen candidates
in P. falciparum cannot be readily used for P. vivax. Establishing
robust P. vivax culture systems, or devising alternative approaches
such as cell-free assays or the generation of chimeric parasites
from other Plasmodium spp. that express P. vivax antigens, will be
essential to scale up functional testing of new P. vivax vaccine can-
didates. However, there has recently been substantial progress in
using cryo-preserved isolates in short term in vitro culture, com-
bined with flow cytometry approaches that allow more sensitive
detection of low level parasitemia (Cho et al., 2016; Roobsoong,
2015). These approaches have provided insights into the rapid
remodelling of reticulocytes upon P. vivax invasion and the strong
selective preference for reticulocytes that are CD71-positive, which
may have implications for P. vivax accumulation in the bone mar-
row (Malleret et al., 2015). If reproducible in many laboratories,
such assays alone may provide a way to test for growth inhibitory
antibodies as well as other functional assays (Grimberg et al.,
2007a). In addition, the recent development of human liver-
chimeric mice that allow blood stage P. vivax infection may provide
an alternative, although perhaps more costly, avenue to functional
analyses (Mikolajczak et al., 2015).
Secondly, P. vivax genomic diversity will need to be tackled
head on. Initial sequencing of a small number of P. vivax clinical
isolates suggests that diversity may be even higher in this species
than in P. falciparum (Neafsey et al., 2012), a finding that has
recently been borne out by much larger genomic studies (Hupalo
et al., 2016; Pearson et al., 2016). Such diversity presents a chal-
lenge in vaccine development, as vaccine-induced immune
responses need to be broadly reactive to different polymorphic
variants or alleles to prevent vaccine escape (Barry et al., 2012;
Conway, 2015). For P. vivax, the immunological significance of
polymorphisms has already been evaluated for a few antigens,
and PvDBPII and PvAMA1 both have significant polymorphisms
that may impact vaccine design (Arnott et al., 2014; King et al.,research – we’ve only just begun. Int. J. Parasitol. (2016), http://dx.doi.org/
6 W.-H. Tham et al. / International Journal for Parasitology xxx (2016) xxx–xxx2008; VanBuskirk et al., 2004). Studies in P. falciparum suggest that
antigenic diversity may not be as extensive as suggested by
sequence analysis (Mamillapalli et al., 2006; Terheggen et al.,
2014) and provide hope that diversity in vaccine antigens can be
overcome. In the case of P. falciparum, diversity in blood-stage tar-
gets is not restricted to the sequence level. Plasmodium falciparum
merozoites can use multiple redundant and partially overlapping
invasion pathways by varying the expression and utilisation of
multiple invasion ligands, and this appears to facilitate evasion of
acquired immunity (Persson et al., 2008). Emerging evidence indi-
cates that P. vivaxmay also use different invasion pathways, which
could similarly contribute to immune evasion and will need to be
considered in vaccine design (Menard et al., 2010; Zimmerman
et al., 2013). Considering diversity at all stages of vaccine develop-
ment, and making full use of available genomic data when design-
ing and testing antigens, must become a key component of
experimental design.
What would an effective P. vivax vaccine look like? While this
review has focussed on blood-stage targets, the long history of sin-
gle stage/single target vaccine trials in P. falciparum suggests that a
vaccine that includes multiple targets may be required for high
efficacy. The recent helpful and detailed definition of a target pro-
duct profile (TPP) for a P. vivax vaccine supports this by emphasis-
ing the importance of blocking transmission as well as preventing
P. vivax malaria (Mueller et al., 2015). If targeting both blood and
transmission stages in a single vaccine seems an ambitious target
for P. falciparum vaccine development, it seems even more so for
P. vivax, given the extremely limited number of antigens that have
been investigated to date. However, the recent upsurge in aware-
ness of P. vivax as a significant global problem, driven by detailed
clinical definitions of severe P. vivax malaria, the existence of P.
vivax drug resistance, and the decline of P. falciparum infection
rates in some parts of the world, means that interest in P. vivax vac-
cine development is growing rapidly. If that interest is to turn into
progress, it needs to be empowered by increased funding. The
funding landscape for P. vivax vaccine development is very differ-
ent now from what it was a decade ago, due to the attention and
support of many global funders. However, the history of P. falci-
parum vaccine development makes it clear that this will not be a
simple task, and significant financial support will be required for
there to be an impact. We can however draw hope from the recent
history of vaccine development in P. falciparum. While a fully
effective vaccine still remains elusive, there is no question that
P. falciparum antigen discovery and testing is currently going
through a rapid acceleration. If we learn from both the positive
and negative aspects of this acceleration, and develop new tools
and approaches to account for the unique nature of P. vivax biology,
P. vivax vaccine development may be poised for a similar
transformation.
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